Neuroprotective and anti‐inflammatory effects of curcumin in Alzheimer's disease: Targeting neuroinflammation strategies

Phytotherapy Research, Journal Year: 2024, Volume and Issue: 38(6), P. 3169 - 3189

Published: April 14, 2024

Abstract Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid‐beta plaques and neurofibrillary tangles, leading to neuronal loss. Curcumin, polyphenolic compound derived from Curcuma longa , has shown potential neuroprotective effects due its anti‐inflammatory antioxidant properties. This review aims synthesize current preclinical data on anti‐neuroinflammatory mechanisms curcumin in context AD, addressing pharmacokinetics, bioavailability, as therapeutic adjunct. An exhaustive literature search was conducted, focusing recent studies within last 10 years related curcumin's impact neuroinflammation role AD. The methodology included sourcing articles specialized databases using specific medical subject headings terms ensure precision relevance. Curcumin demonstrates significant properties modulating neuroinflammatory pathways, scavenging reactive oxygen species, inhibiting production pro‐inflammatory cytokines. Despite potential, challenges remain regarding limited bioavailability scarcity comprehensive human clinical trials. emerges promising adjunct AD multimodal benefits. However, further research required overcome establish effective dosing regimens subjects. Developing novel delivery systems formulations may enhance treatment.

Language: Английский

---

Gut Microbiota-Based Interventions for Parkinson’s Disease: Neuroprotective Mechanisms and Current Perspective

Probiotics and Antimicrobial Proteins, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 15, 2025

Language: Английский

---

New insights in animal models of neurotoxicity-induced neurodegeneration

Frontiers in Neuroscience, Journal Year: 2024, Volume and Issue: 17

Published: Jan. 8, 2024

The high prevalence of neurodegenerative diseases is an unintended consequence the longevity population, together with lack effective preventive and therapeutic options. There great pressure on preclinical research, both old new models are required to increase pipeline drugs for clinical testing. We review here main neurotoxicity-based animal leading central neurodegeneration. Our focus was studying how changes in neurotransmission neuroinflammation, mainly rodent models, contribute harmful processes linked majority currently use mimic Parkinson's disease (PD) Alzheimer's (AD), which most common conditions older adults. AD age-related dementia, whereas PD movement disorder also cases dementia. Several natural toxins xenobiotic agents induce dopaminergic neurodegeneration can reproduce neuropathological traits PD. literature analysis MPTP, 6-OH-dopamine, rotenone suggested latter as a useful model when specific doses were administrated systemically C57BL/6 mice. Cholinergic modelled toxin scopolamine, screening protective against cognitive decline AD. have been used neuroinflammation-based dementia AD, including lipopolysaccharide (LPS), streptozotocin, monomeric C-reactive protein. bacterial agent LPS makes testing anti-inflammatory therapies halt development severity However, neurotoxin might be more than genetic drug discovery but that not case where they cannot beat developments transgenic mouse models. Overall, we should work using all available either

Language: Английский

---

Real-World Safety Data of the Orphan Drug Onasemnogene Abeparvovec (Zolgensma®) for the SMA Rare Disease: A Pharmacovigilance Study Based on the EMA Adverse Event Reporting System

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(3), P. 394 - 394

Published: March 19, 2024

The recent introduction of the innovative therapy, onasemnogene abeparvovec (Zolgensma

Language: Английский

---

Cognitive function in SMA patients with 2 or 3 SMN2 copies treated with SMN-modifying or gene addition therapy during the first year of life

European Journal of Paediatric Neurology, Journal Year: 2024, Volume and Issue: 51, P. 17 - 23

Published: May 8, 2024

Spinal muscular atrophy (SMA) is a neuromuscular disease, causing progressive muscle weakness due to loss of lower motoneurons. Since 2017, three therapies, two modifying gene transcription and one adding the defective gene, have been approved with comparable efficacy on motor outcome. Data cognitive outcomes treated SMA type 1 patients limited. The aim this study was evaluate function in symptomatic presymptomatic or SMN2 copies who received SMN-modifying gene-addition therapy first year life.

Language: Английский

---

Therapeutic targeting of immunometabolism reveals a critical reliance on hexokinase 2 dosage for microglial activation and Alzheimer’s progression

Cell Reports, Journal Year: 2024, Volume and Issue: 43(7), P. 114488 - 114488

Published: July 1, 2024

Language: Английский

---

The interactions between energy homeostasis and neurovascular plasticity

Nature Reviews Endocrinology, Journal Year: 2024, Volume and Issue: 20(12), P. 749 - 759

Published: July 25, 2024

Language: Английский

---

Epigenetic Mechanisms Underlying Sex Differences in Neurodegenerative Diseases

Biology, Journal Year: 2025, Volume and Issue: 14(1), P. 98 - 98

Published: Jan. 19, 2025

Neurodegenerative diseases are characterized by profound differences between females and males in terms of incidence, clinical presentation, disease progression. Furthermore, there is evidence suggesting that sensitivity to medical treatments may exist the two sexes. Although role sex hormones chromosomes driving differential susceptibility these well-established, molecular alterations underlying remain poorly understood. Epigenetic mechanisms, including DNA methylation, histone tail modifications, activity non-coding RNAs, strongly implicated pathogenesis neurodegenerative diseases. While it known epigenetic mechanisms play a crucial sexual differentiation distinct patterns characterize males, sex-specific have been largely overlooked studies aiming identify associated with This review aims provide an overview processes central nervous system, main three diseases, Alzheimer’s disease, Parkinson’s amyotrophic lateral sclerosis. Understanding sex-related essential for developing personalized interventions account unique landscapes each sex.

Language: Английский

---

Loss of endothelial CD2AP causes sex-dependent cerebrovascular dysfunction

Neuron, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

---

Global, regional, and national burden of four major neurological diseases in women from 1990 to 2021

Frontiers in Public Health, Journal Year: 2025, Volume and Issue: 13

Published: April 9, 2025

The burden of neurological diseases in women is underestimated. This study aimed to estimate the pattern and trend four major nervous system women. Utilizing data from GBD Study 2021 on incidence disability-adjusted life-years (DALYs) Alzheimer's disease (AD) other dementias, Parkinson's disease, multiple sclerosis, idiopathic epilepsy 1990 2021. We estimated trends by age socio-demographic index (SDI), globally, regionally, nationally, using Estimated annual percentage changes (EAPC), Spearman correlation analysis projected future with Bayesian age-period-cohort (BAPC) model. In 2021, an 6191564.2, 572999.9, 1536118.7, 39191.7 new cases female AD were reported a significant increase age-standardized rate (ASIR) Contrary, DALY (ASDR) decreased sclerosis. dementias prevalent among worldwide, followed regional country disparities. There are also difference patterns SDI. BAPC model projects that 2050, ASIR disorders will continue increase. serious global health challenge. Given disparities varying DALYs, there urgent need for tailored prevention healthcare approaches mitigate worldwide.

Language: Английский

---